| |
Efficacy and Safety of MK-5172, MK-8742, and Sofosbuvir for Chronic Infection With Hepatitis C Virus Genotypes 1 and 3 (MK-5172-074)
|
| |
| |
http://www.clinicaltrials.gov/ct2/show/NCT02133131?term=MK-5172&rank=10
This study is not yet open for participant recruitment.
Verified May 2014 by Merck Sharp & Dohme Corp
Inclusion Criteria:
·
HCV RNA ≥10,000 IU/mL in peripheral blood at the time of screening
·
documented chronic HCV GT1 or GT3 infection
·
negative or positive history of liver cirrhosis based on liver biopsy, Fibroscan, or FibroSure ® (Fibrotest®)
·
treatment naïve to all anti-HCV treatment
Exclusion Criteria:
·
has evidence of decompensated liver disease
·
is coinfected with hepatitis B virus (e.g. hepatitis B surface antigen positive) or human immunodeficiency virus
·
history of malignancy ≤5 years prior to signing informed consent, or is under evaluation for other active or suspected malignancy
·
has cirrhosis and liver imaging within 6 months of Day 1 showing evidence of hepatocellular carcinoma (HCC) or is under evaluation for HCC
·
has clinically-relevant drug or alcohol abuse within 12 months of screening
·
has any of the following conditions: organ transplants other than cornea and hair, poor venous access that precludes routine peripheral blood sampling, history of gastric surgery or malabsorption disorders, or any medical condition requiring, or likely to require, chronic systemic administration of corticosteroids during the course of the trial
·
history of chronic hepatitis not caused by HCV
|
|
| |
| |
|
|
|
